Our cofounders sat with AWS bio leaders to discuss generative models of biology

Today, organizations are looking to harness the power of generative AI, including foundation models (FMs) and large language models (LLMs) to innovate faster to reinvent patient outcomes. While this has created a lot of hype, the adoption of these technologies in real-world drug development is still a challenge for most organizations.

Amrita Sarkar, Principal Healthcare and Life Sciences Business Development Manager at AWS speaks to two startups of AWS Generative AI Accelerator’s first cohort, Tahoe (formerly Vevo) and Nosis Bio. These startups share how they are successfully applying generative AI to accelerate their research initiatives, and candidly talk about their learnings as they try to separate the hype from the hope.

This Executive Conversation is part of a series of discussions held with leaders who are pushing the frontiers of the healthcare and life sciences industry with cloud technology. We were joined by Nosis cofounders Jim Martineau and Seth Myers, and Tahoe cofounders Nima Alidoust and Johnny Yu.